retatrutide triple agonist phase 2 obesity trial glp-1 gip glucagon nejm 2023 Medscape 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”

Others remain on therapy long-term because obesity is a chronic disease requiring ongoing management, much like diabetes or hypertension

Endocrinology 153(2):647658 Mietlicki-Baase EG et al (2013) The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors

A mechanism for regulated insulin delivery to the brain

Research has shown a 20% increase in calories consumed at a meal when alcohol was consumed before the meal

There were clinical studies have explored the connection between GLP-1 receptor agonists and diabetic, these medications dont appear to have major impact on sarcopenia [57, 58]

Takakura Y, Masuda S, Tokuda H, Nishikawa M, Hashida M